Posted by Michael Wonder on 03 Jun 2024
Zealand Pharma announces positive CHMP opinion for dasiglucagon for treatment of severe hypoglycemia in diabetes from European Medicines Agency
31 May 2024 - Zealand Pharma today announced that the CHMP of the EMA has issued a positive opinion recommending granting marketing authorisation for dasiglucagon solution for injection in the treatment of severe hypoglycaemia in adults, adolescents, and children aged 6 years and over with diabetes mellitus.
In September 2022, Zealand entered into a global license and development agreement with Novo Nordisk to commercialise Zegalogue.
